BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Myotonic Dystrophy Type 1 readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Myotonic Dystrophy Ty
 pe 1\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06185764-10843@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20270202
DTEND;VALUE=DATE:20270203
SUMMARY:VX-670: Phase 1/2 readout est. (NCT06185764)
DESCRIPTION:VX-670\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A Phase
  1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
 \nEstimated primary completion: 2 February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06185764
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06926621-10843@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290130
DTEND;VALUE=DATE:20290131
SUMMARY:VX-670: Phase 2 readout est. (NCT06926621)
DESCRIPTION:VX-670\, phase 2\, Myotonic Dystrophy Type 1.\nStudy: A Study o
 f Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dy
 strophy Type I\nEstimated primary completion: 30 January 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/vx-670#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06926621
URL:https://assetmemo.bio/drug/vx-670#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844214-11342@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:SAR446268: Phase 1/2 readout est. (NCT06844214)
DESCRIPTION:SAR446268\, phase 1/2\, Myotonic Dystrophy Type 1.\nStudy: A St
 udy to Investigate the Safety\, Tolerability\, and Efficacy of SAR446268\,
  an Adeno-associated Viral Vector-mediated Gene Therapy in Participants Ag
 ed 10 to 55 Years of Age With Non-congenital Myotonic Dystrophy Type 1\nEs
 timated primary completion: 28 February 2029. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/sar446268#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06844214
URL:https://assetmemo.bio/drug/sar446268#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07008469-11253@assetmemo.bio
DTSTAMP:20261121T005431Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Delpacibart etedesiran: Phase 3 readout est. (NCT07008469)
DESCRIPTION:Delpacibart etedesiran\, phase 3\, Myotonic Dystrophy Type 1.\n
 Study: Global Open-Label Extension Study of Del-desiran for the Treatment 
 of DM1\nEstimated primary completion: October 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/delpacibart-etedesiran#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07008469
URL:https://assetmemo.bio/drug/delpacibart-etedesiran#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
